Tadahiko Kubo1, Shoji Shimose2, Jun Fujimori2, Taisuke Furuta2, Mitsuo Ochi2. 1. Department of Orthopaedic Surgery, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan. Electronic address: kubot@hiroshima-u.ac.jp. 2. Department of Orthopaedic Surgery, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
Abstract
PURPOSE: The objective of this systematic review is to provide an unprecedented summary of the prognostic impact of PAX3/7-FOXO1 fusion status in alveolar rhabdomyosarcoma. METHODS: Studies evaluating PAX3/7-FOXO1 fusion gene or its variants as a prognostic marker were systematically searched and comparative meta-analysis of overall survival was carried out. RESULTS: A total of 7 studies comprising 993 patients with rhabdomyosarcoma were included. Three eligible studies showed no significant difference of survival between fusion positive and negative alveolar rhabdomyosarcoma. Four eligible studies showed that PAX3-FOXO1 fusion variant may indicate a lower survival probability than PAX7-FOXO1, although the effect did not reach a level of statistical significance (pooled hazard ratios, 1.66; 95% CI, 0.95-2.89; p=0.07). CONCLUSIONS: There was no significant difference in the overall survival between patients with the positive and negative fusion gene, but there were indications of PAX3-FOXO1 being an unfavorable prognostic factor.
PURPOSE: The objective of this systematic review is to provide an unprecedented summary of the prognostic impact of PAX3/7-FOXO1 fusion status in alveolar rhabdomyosarcoma. METHODS: Studies evaluating PAX3/7-FOXO1 fusion gene or its variants as a prognostic marker were systematically searched and comparative meta-analysis of overall survival was carried out. RESULTS: A total of 7 studies comprising 993 patients with rhabdomyosarcoma were included. Three eligible studies showed no significant difference of survival between fusion positive and negative alveolar rhabdomyosarcoma. Four eligible studies showed that PAX3-FOXO1 fusion variant may indicate a lower survival probability than PAX7-FOXO1, although the effect did not reach a level of statistical significance (pooled hazard ratios, 1.66; 95% CI, 0.95-2.89; p=0.07). CONCLUSIONS: There was no significant difference in the overall survival between patients with the positive and negative fusion gene, but there were indications of PAX3-FOXO1 being an unfavorable prognostic factor.
Authors: David O Azorsa; Peter K Bode; Marco Wachtel; Adam Tai Chi Cheuk; Paul S Meltzer; Christian Vokuhl; Ulrike Camenisch; Huy Leng Khov; Beata Bode; Beat W Schäfer; Javed Khan Journal: Mod Pathol Date: 2020-12-09 Impact factor: 8.209
Authors: Simon C Y Chow; Randolph H L Wong; Innes Y P Wan; Ka Fai To; Song Wan; Malcolm J Underwood; Calvin S H Ng Journal: J Med Case Rep Date: 2015-07-17
Authors: Samuel Abbou; Sarah Finstuen-Magro; Brigit McDannell; Michelle Feenstra; Abigail Ward; David S Shulman; Birgit Geoerger; Joadly Duplan; Hannah Comeau; Katherine A Janeway; Kelly Klega; Brian D Crompton Journal: Mod Pathol Date: 2022-03-28 Impact factor: 8.209